

## University of California, Berkeley U.C. Berkeley Division of Biostatistics Working Paper Series

Year 2013

Paper 307

# Targeted Estimation of Variable Importance Measures with Interval-Censored Outcomes

Stephanie Sapp<sup>\*</sup> Mark J. van der Laan<sup>†</sup>

Kimberly Page<sup>‡</sup>

\*University of California - Berkeley, sapp@berkeley.edu

<sup>†</sup>University of California - Berkeley, laan@berkeley.edu

<sup>‡</sup>University of California - San Francisco, kpage@psg.ucsf.edu

This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder.

http://biostats.bepress.com/ucbbiostat/paper307

Copyright ©2013 by the authors.

## Targeted Estimation of Variable Importance Measures with Interval-Censored Outcomes

Stephanie Sapp, Mark J. van der Laan, and Kimberly Page

#### Abstract

In most experimental and observational studies, participants are not followed in continuous time. Instead, data is collected about participants only at certain monitoring times. These monitoring times are random, and often participant specific. As a result, outcomes are only known up to random time intervals, resulting in interval-censored data. In contrast, when estimating variable importance measures on interval-censored outcomes, practitioners often ignore the presence of interval-censoring, and instead treat the data as continuous or right-censored, applying ad-hoc approaches to mask the true interval-censoring. In this paper, we describe Targeted Minimum Loss-based Estimation methods tailored for estimation of variable importance measures with interval-censored outcomes. We demonstrate the performance of the interval-censored TMLE procedure through simulation studies, and apply the method to analyze the effects of a variety of variables on spontaneous hepatitis C virus clearance among injection drug users, using data from the "International Collaboration of Incident HIV and HCV in Injecting Cohorts" project.

## **1** Introduction

Determining the effect importance of a large collection of biomarkers on an outcome is a frequent goal in applications involving epidemiology. For example, epidemiologists often wish to determine the effects of a variety of behavioral and biological factors on health outcomes. In practice, epidemiological data is not collected in continuous time, and is rather only measured at random monitoring times, resulting in interval-censored outcomes.

Practitioners often ignore interval-censoring when conducting their analysis. One common approach involves using a misspecified parametric model and forward imputing the outcome to the final time of interest. For example, in analyzing factors associated with the interval-censored outcome of spontaneous hepatitis C virus clearance within 2 years of incident infection, Grebely et al. (2012a) used a logistic regression approach. Their analysis both assumed a logistic relationship between variables and outcome, and ignored interval-censoring of clearance by forward imputing the clearance outcome to the 2 year endpoint.

Another approach ignoring interval censoring involves obtaining estimates using targeted learning methodology, but forward imputing the outcome to the final time of interest. This approach is more principled in the sense that the estimates obtained would be valid in the *absence* of interval-censoring, but nonetheless fails to account for interval-censoring. For example, Bembom et al. (2009) estimated the effects of a variety of biomarkers on viral load outcome under HIV treatment change using Targeted Minimum Loss-based Estimation of variable importance measures, but ignored interval-censoring of the viral load outcome, and instead effectively used forward imputation.

To account for interval-censoring, nonparametric maximum likelihood estimators (NPMLE) for the marginal distribution of an interval-censored event time have been studied for various types of interval-censored data. For example, Groeneboom and Wellner (1992) study the NPMLE for "case 1" data, and Geskus and Groeneboom (1999) study the NPMLE for "case 2" data. "Case 1", or current status, data is obtained when participants are only observed once, at a fixed monitoring time. At this monitoring time, we observe an indicator of whether or not the event has occurred. "Case 2" data involves monitoring participants twice, and at each monitoring time, observing an indicator of whether or not the event has occurred. However, these NPMLE approaches only estimate the marginal event time distribution, and thus do not provide estimates of covariate effects on the outcome event.

Semiparametric regression models for interval-censored data have been proposed to analyze the effects of various covariates on the outcome event. Proportional hazards models have been studied by, for example, Cai and Betensky (2003), Huang and Wellner (1997), and Finkelstein (1986). Proportional odds models have

been studied by, for example, Rabinowitz, Betensky, and Tsiatis (2000), Rossini and Tsiatis (1996), and Huang and Wellner (1997). Accelerated failure time models have been studied by, for example, Tian and Cai (2006), Huang and Wellner (1997), and Rabinowitz, Tsiatis, and Aragon (1995). In these models, effect estimates are given by the estimated regression coefficient, and hence still suffer from model misspecification.

In this paper, we propose making less restrictive modeling assumptions and clearly defining the target parameter of interest when analyzing the effects of a variety of variables on an interval-censored outcome. In particular, we define variable importance measures (VIM) as functions of the true data generating distribution, instead of as coefficients in possibly misspecified models. We use a nonparametric statistical model, which makes no statistical assumptions about the form of the underlying true data generating distribution, and only make non-testable assumptions about the causal model generating the data.

We develop Targeted Minimum Loss-based Estimation (TMLE) methods to estimate VIM in the presence of interval-censored outcomes. Our interval-censored TMLE procedure (IC-TMLE) provides consistent estimates, valid inference, and a variety of other desirable properties under regularity conditions. We show that ignoring interval-censoring leads to incorrect VIM estimates and inference, and demonstrate the superior performance of IC-TMLE. We apply IC-TMLE to estimate VIM of spontaneous hepatitis C virus (HCV) clearance among injection drug users, using data from the "International Collaboration of Incident HIV and HCV in Injecting Cohorts" (InC3) project.

The remainder of our paper is organized as follows. We formalize the observed data structure in Section 2. The target VIM parameter, including two formulation possibilities, are presented in Section 3. We discuss estimation of VIM and the IC-TMLE algorithm in Section 4. Simulation study results appear in Section 5. We use IC-TMLE to analyze data from the InC3 project in Section 6. Finally, we conclude in Section 7.

## 2 Data Structure

#### 2.1 Observed Data

We consider the following observed data structure. Observations, consisting of time-varying covariates L(t) and time-to-event outcome process Y(t), are collected from each participant i = 1, ..., n at different discrete monitoring times t. The outcome process Y(t) indicates whether the event has been observed by time t. Monitoring process  $\Delta(t)$  indicates whether monitoring occurs at time t. Each participant

is observed at time t = 0: we measure baseline covariates W = L(0), and assign or observe binary "treatment" A for which we want to estimate a VIM. Note that the definitions of A and W depend upon the VIM being analyzed. Since our outcome of interest is a time-to-event, we assume the event has not yet occurred at baseline, and the outcome process Y(t) only jumps once.

Although, for simplicity, this paper only discusses the case of a single treatment at time 0, the approach described in this paper can be easily extended to treatments at multiple time points. Note that A does not need to be an actual treatment: it may be a behavioral or biological marker observed at baseline. We label subsequent monitoring times as  $t = 1, 2, ..., \tau$ , where  $\tau$  is the monitoring time at which we aim to measure the final outcome. Note that the *t* numerical labels can be determined by bucketing the true monitoring times into  $\tau$  intervals, or by simply numbering the visits. Since not every participant is observed at every monitoring time, we encode the measurements at every monitoring time *t* as the tuple  $(\Delta(t), \Delta(t)L(t), \Delta(t)Y(t)) = (\Delta(t), L^*(t), Y^*(t))$ , so that the covariates and outcome process are defined at every *t*. If we do observe data at time *t*, the true L(t) and Y(t) values are used, since  $\Delta(t) = 1$ . Otherwise, monitoring does not occur at time *t*, so  $\Delta(t) = 0$ , and we use degenerate values for L(t) and Y(t). This observed data structure can be represented, ordered in the assumed collection order, as the random variable  $O = (W, A, {\Delta(t), L^*(t), Y^*(t)}_{t=1}^{\tau})$ .

Since our interest is in observing the value of  $Y(\tau)$ , the missing indicator of primary interest is  $\Delta(\tau)$ . We view the intermediate  $\Delta(t)$  indicators and associated measurements as simply intermediate data, rather than missing indicators to intervene upon. To clarify this distinction, we use the notation  $L' = {\Delta(t), L^*(t), Y^*(t)}_{t=1}^{\tau-1}$  as a single variable indicating all intermediate data,  $Y = Y^*(\tau)$  as the final outcome of interest, and  $\Delta = \Delta(\tau)$  as the indicator of monitoring at that final time. Using this notation, we represent the observed data structure as  $O = (W, A, L', \Delta, Y)$ .

#### 2.2 Statistical and Causal Model

We assume the following non-parametric structural causal model (NPSCM), as in Pearl (2000), which encodes the non-testable causal assumptions about the time-ordering of the observed data.

In equations (1),  $U = (U_W, U_A, U_{L'}, U_{\Delta}, U_Y)$  are unobserved exogenous random variables, while the functions f are deterministic and not restricted to any functional form. Each endogenous variable  $W, A, L', \Delta, Y$  is only a function of its parents (variables preceding it in the assumed time ordering), and its corresponding U random variable, which captures additional randomness in each endogenous variable not accounted for by the parents alone.

Our statistical model is indexed by the functions f and the random variable U. We put no restrictions on their statistical distributions. We will make randomization assumptions in the next section, which are non-testable *causal* assumptions. However, our *statistical* model remains semiparametric because we make no distributional form assumptions. Hence, the observed data O is a random variable with data generating distribution P, which is an element of semiparametric statistical model  $\mathcal{M}$ , i.e.,  $O \sim P \in \mathcal{M}$ .

## **3** Target Parameter

#### **3.1** Formulation Possibilities

We focus on the risk difference parameter, and consider two possible formulations of this target parameter.

#### 3.1.1 Static Intervention Formulation

The first possible target parameter formulation is given by:

$$\Psi_{static}^{F} = E \left[ Y^{A=1,\Delta=1} - Y^{A=0,\Delta=1} \right] = E \left[ Y^{1,1} \right] - E \left[ Y^{0,1} \right]$$
(2)

The following static intervention on the NPSCM yields the counterfactual outcome  $Y^{a,1}$ :

$$d_{(a,1)}:\begin{cases} A=a\\ \Delta=1 \end{cases}$$
(3)

The above intervention is straightforward to understand: we set the treatment at baseline to the desired value, and ensure that monitoring occurs at the final time  $\tau$ , so that we can check whether the event of interest has occurred. Using the NPSCM, counterfactual data following the intervention (3) can be generated as follows. First, draw U. Then, generate  $W = f_W(U_W)$ . Next, generate  $L'^{,a} = f_{L'}(W, a, U_{L'})$ . Finally, generate  $Y^{a,1} = f_Y(W, a, L', 1)$ .

#### 3.1.2 Stochastic Intervention Formulation

To reflect the fact that our parameter of interest is whether the event of interest has occurred by time  $\tau$ , and hence does not necessarily depend on being monitored *at* exactly time  $\tau$ , we introduce the following redefinition of the data. At time t = 0, define  $Y^{\#}(0) = Y^{*}(0)$ ,  $\Delta^{\#}(0) = \Delta(0)$ , and  $L^{\#}(0) = L^{*}(0)$ . At times t > 0:

$$Y^{\#}(t) = Y^{\#}(t-1) \text{ if } I(Y^{\#}(t-1)=1)$$
  

$$\Delta^{\#}(t) = \Delta^{\#}(t-1) \text{ if } I(Y^{\#}(t-1)=1)$$
  

$$L^{\#}(t) = L^{\#}(t-1) \text{ if } I(Y^{\#}(t-1)=1)$$
(4)

The above redefinition sets all values of the data deterministically after observing that the event of interest has occurred. Note that  $Y^{\#}(t) = 1$  implies that  $\Delta^{\#}(t) = 1$ . Also, note that  $Y^{\#}(t)$  and  $\Delta^{\#}(t)$  will equal  $Y^{*}(t)$  and  $\Delta(t)$ , unless  $\Delta(t) = 0$  and  $Y^{*}(t) = 0$ , respectively. This is due to the fact that the data redefinition only changes the values of  $Y^{*}(t)$  and  $\Delta(t)$  if they are not already equal to one. Using these observations, we can express the data redefinition (4) equivalently as:

$$\begin{aligned}
Y^{\#}(t) &= Y^{*}(t) + (1 - Y^{*}(t)) Y^{\#}(t - 1) \\
\Delta^{\#}(t) &= \Delta(t) + (1 - \Delta(t)) \Delta^{\#}(t - 1) Y^{\#}(t - 1) \\
L^{\#}(t) &= L^{\#}(t - 1) Y^{\#}(t - 1) + L^{*}(t) (1 - Y^{\#}(t - 1))
\end{aligned} \tag{5}$$

Using redefinition (5), our observed data structure is now  $O^{\#} = (W, A, L'^{\#}, \Delta^{\#}, Y^{\#})$ , where  $\Delta^{\#} = \Delta^{\#}(\tau)$  and  $Y^{\#} = Y^{\#}(\tau)$ .

With this redefinition in hand, we now define a second possible target parameter:

$$\Psi^{F}_{stochastic} = E\left[Y^{\#,A=1,\Delta=\delta} - Y^{\#,A=0,\Delta=\delta}\right]$$
$$= E\left[Y^{\#,1,\delta}\right] - E\left[Y^{\#,0,\delta}\right]$$
(6)

The following stochastic intervention on the NPSCM (involving a static intervention on baseline treatment *A*, and stochastic intervention on the monitoring mechanism  $\Delta^{\#}$ ) yields the counterfactual outcome  $Y^{\#,a,\delta}$ :

$$d_{(a,\delta)}: \begin{cases} A = a \\ \Delta^{\#} = \delta = \begin{cases} 1 & \text{if } Y^{\#}(\tau - 1) = 0 \\ \Delta^{\#}(\tau - 1) & \text{if } Y^{\#}(\tau - 1) = 1 \end{cases}$$
(7)

The stochastic intervention on the monitoring process  $\Delta^{\#}$  ensures that we enforce monitoring at time  $\tau$  if we have not yet observed the event of interest, and

do not intervene on the monitoring process if the event of interest has already been observed (in that case,  $\Delta^{\#} = \Delta^{\#}(\tau - 1)$  already, by the redefinition of the data).

As in the static intervention case, we can use the NPSCM to generate counterfactual data following the intervention (7). We begin by drawing *U*. Then, we generate  $W = f_W(U_W)$ . Next, we generate  $L' = f_{L'}(W, a, U_{L'})$ . Finally, we compute the value  $\delta$  from *L'*, and generate  $Y = f_Y(W, a, L', \delta)$ .

#### 3.1.3 Equivalence of Proposed Intervention Formulations

While the stochastic intervention formulation might seem more desirable, since it does not require intervention when the event of interest is already known to have occurred, both formulations result in the same statistical parameter. For a proof, see Appendix C. In the remainder of this paper, we use the simpler static intervention representation of the parameter. Hence, we our target VIM parameter is:

$$\Psi = E_W \left[ E_{L'} \left[ E \left[ Y | W, A = 1, L', \Delta = 1 \right] \right] \right] - E_W \left[ E_{L'} \left[ E \left[ Y | W, A = 0, L', \Delta = 1 \right] \right] \right]$$
(8)  
=  $\Psi_1 - \Psi_0$ 

In principle, the two formulations possibilities would require two sets of identifiability assumptions, as discussed in Appendix A and Appendix B. However, we show in Appendix C that the identifiability assumptions are equivalent.

The causal assumptions needed for (8) to be identifiable from the distribution of the observed data are: consistency, randomization, and positivity. The consistency assumption requires that intervening on treatment to set A = a and intervening on monitoring to set  $\Delta = 1$  in the NPSCM yields the observed outcome Y if the observed treatment and monitoring values equal a and 1, respectively. The randomization assumption requires that, given the observed past, treatment and monitoring are independent of counterfactual outcomes. The positivity assumption requires that, given the observed past, the conditional probability of treatment A = a, and monitoring  $\Delta = 1$ , are positive.

Note that even in the case that the causal assumptions fail to hold, the parameter (8) still remains an interesting variable importance measure of the effect of A on the outcome Y. In that case, (8) represents the effect of A on Y, controlling for the measured confounders W, and ensuring that monitoring occurs at the final time of interest.

#### **3.2 Representation as Function of Iterated Conditional Means**

Observe that the VIM  $\psi$  is a function of the density P(O), since, if P(O) were known, we could calculate (8) exactly: first compute conditional distributions from

the full joint distribution, then perform integrations.

Although  $\psi$  depends on *P*, we do not need to know *all* of *P* in order to calculate  $\psi$ . This can be seen by factorizing *P*(*O*) as follows:

$$P(O) = P_{W}(W) P_{A}(A|W) P_{L'}(L'|A,W) P_{\Delta}(\Delta|W,A,L') P_{Y}(Y|W,A,L',\Delta) = Q_{W} g_{A} Q_{L'} g_{\Delta} Q_{Y}$$
(9)

Now, observe that our VIM parameter (8) only depends on the distribution *P* through its *Q* factors in (9), and hence may be represented as  $\psi(Q)$ . Furthermore, observe that  $\psi(Q)$  may be represented as an iterative conditional expectation: first conditioning on  $\{L', W\}$ , then on only  $\{W\}$ . This can be seen as follows. We first introduce some additional notation:

$$\begin{array}{lcl}
\bar{Q}_{Y}^{a,1} &= & E\left[Y|W,A=a,L',\Delta=1\right] \\
\bar{Q}_{L'}^{a,1} &= & E_{L'}\left[\bar{Q}_{Y}^{a,1}|W,A=a\right] \\
\bar{Q}_{W}^{a,1} &= & E_{W}\left[\bar{Q}_{L'}^{a,1}\right] \\
\end{array}$$
(10)

Using the conditional mean notation (10), we can re-express the components of our target parameter as follows:

$$\Psi_{a} = E_{W} \left[ E_{L'} \left[ E\left[Y|W, A = a, L', \Delta = 1\right] \right] \right]$$

$$= E_{W} \left[ E_{L'} \left[ \bar{Q}_{Y}^{a,1} \right] \right]$$

$$= \bar{Q}_{W}^{a,1}$$
(11)

## **4** Estimation

#### 4.1 Targeted Minimum Loss-based Estimation (TMLE) Overview

Targeted Minimum Loss-based Estimation (TMLE) is a general framework for constructing estimators of a statistical parameter  $\psi$  under a semiparametric model. The procedure consists of two steps. The first step involves obtaining an initial estimate  $\hat{Q}$  of the portion Q of the data-generating distribution P that is needed to calculate  $\psi$ . The second step obtains an update  $\hat{Q}^*$  of  $\hat{Q}$  through a fluctuation that is targeted

toward optimizing the bias-variance trade-off for  $\psi$ . Finally, the TMLE estimate of  $\psi$  is given by the substitution (plug-in) estimate  $\hat{\psi} = \psi(\hat{Q}^*)$ .

We recommend using Super Learning to obtain the initial estimate of Q. Super Learning is a machine learning algorithm which involves proposing a library of candidates estimators, and using cross-validation to data-adaptively select the weighted combination of the candidates that minimizes the cross-validated risk. Through this process, Super Learning does not make any parametric assumptions about the form of density estimated. We refer to van der Laan, Polley, and Hubbard (2007) and van der Laan and Rose (2011) for additional discussion.

Since Super Learning (and any other density estimation procedure) is tailored for the estimation of Q, its bias-variance trade-off is not optimal for  $\psi$ . This explains the need for the updating step in TMLE. In the updating step, we use the initial estimate as a fixed offset, and fluctuate it by performing parametric regression with a so-called "clever covariate", implied by the efficient influence curve, that is constructed for optimal bias-variance trade-off with respect to  $\psi$ . For additional details, we refer the reader to van der Laan and Rubin (2006) and van der Laan and Rose (2011).

Under regularity conditions, the resulting TMLE estimator  $\hat{\psi}$  has the property that

$$\hat{\psi} - \psi_0 \approx \frac{1}{n} \sum_{i=1}^n D^*(O_i) \tag{12}$$

where  $\psi_0$  is the true parameter value, and  $D^*$  is the efficient influence curve. Satisfying (12) results in many desirable properties. In particular, such an estimator is asymptotically linear, consistent, and efficient. Asymptotic linearity refers to the empirical mean representation, which allows us to make use of the Central Limit Theorem and obtain valid inference. Consistency means our estimate is asymptotically unbiasedness, in the sense that  $\hat{\psi}$  approaches the true value  $\psi_0$  as sample size increases. Efficiency means that  $\hat{\psi}$  has the minimum asymptotic variance (implied by the efficient influence curve) among all asymptotically linear unbiased estimators. Furthermore, a TMLE estimator is well-defined, in the sense that it does not suffer from multiple solutions. It is a substitution estimator, and thus respects global constrains (for example, if  $\psi$  is a probability, the TMLE procedure will result in an estimate between 0 and 1). The TMLE procedure is also double robust, and has good performance for finite samples. For a additional details, we refer the reader to van der Laan and Rubin (2006) and van der Laan and Rose (2011).



#### 4.2 Efficient Influence Curve

In order to proceed with the TMLE procedure, we need to determine the efficient influence curve (also known as the canonical gradient) of  $\psi$ , which will allow us to construct the clever covariate needed for the updating step of TMLE, as described in Section 4.1.

As shown in Section 3.2, our VIM parameter of interest,  $\psi$ , only depends on *P* through *Q*. As a result, we may derive the canonical gradient for  $\psi$  by first finding any gradient *D* in a model in which *g* is known, and then projecting that gradient into the tangent space of *Q* to obtain the canonical gradient.

Furthermore, from Section 3.2,  $\psi$  may be represented as an iterative conditional expectation. As a result, van der Laan and Gruber (2011) show that the efficient influence curve for  $\psi$  is:  $D^* = D_Y^* + D_{L'}^* + D_W^*$ . We use the notation  $D_Z^* = \Pi(D|T_Z)$  to represent the projection of *D* onto the tangent space  $T_Z$  of  $Q_Z$ , for an arbitrary random variable *Z*. The  $D^*$  components are given by:

$$D_{Y}^{*} = \frac{I(A = a, \Delta = 1)}{g_{A}(a|W) g_{\Delta}(1|W, a, L')} \left(Y - \bar{Q}_{Y}^{a,1}\right) \\D_{L'}^{*} = \frac{I(A = a)}{g_{A}(a|W)} \left(\bar{Q}_{Y}^{a,1} - \bar{Q}_{L'}^{a,1}\right) \\D_{W}^{*} = \bar{Q}_{L'}^{a,1} - \psi(\bar{Q}_{W}^{a,1})$$
(13)

#### 4.3 Interval-Censored TMLE of Variable Importance Measures

Following the general interval-censored TMLE development of Carone, Petersen, and van der Laan (2012) and the TMLE of an intervention specific mean outcome described in van der Laan and Gruber (2011), we estimate variable importance measures in the presence of interval-censored outcomes using the following IC-TMLE algorithm. Note that, although the parametric fluctuation could take different forms, the logistic regression model used below ensures that the fluctuations respect the characteristics of the observed data. For further discussion, see Gruber and van der Laan (2010).

We begin by obtaining an initial estimate  $\bar{Q}_{Y,n}^{a,1}$  of the first conditional mean outcome  $\bar{Q}_Y^{a,1} = E[Y|W, A = a, L', \Delta = 1]$  by regressing Y onto  $\{W, A = a, L', \Delta = 1\}$ . This initial estimate can be obtained using, for example, parametric logistic regression or data-adaptive Super Learning. Second, we fluctuate this initial estimate to obtain an updated estimate  $\bar{Q}_{Y,n}^{a,1,*}$ . To do the update, we use the initial estimate as a fixed offset, and perform a univariate regression of Y onto the clever covariate  $\underline{I(A=a,\Delta=1)}^{a,1,*}$ .

Coll 8A80 or of Biostatistics Research Archive Next, we obtain an initial estimate  $\bar{Q}_{L',n}^{a,1}$  of the second conditional mean outcome  $\bar{Q}_{L'}^{a,1} = E[\bar{Q}_Y^{a,1}|W,A=a]$  by regressing the TMLE  $\bar{Q}_{Y,n}^{a,1,*}$  from the previous step onto  $\{W, A = a\}$ . As before, this initial estimate is then fluctuated to obtain an updated estimate  $\bar{Q}_{L',n}^{a,1,*}$ . The update is obtained by using the initial estimate as a fixed offset in a univariate regression of the TMLE  $\bar{Q}_{Y,n}^{a,1,*}$  onto the clever covariate  $\frac{I(A=a)}{g_A}$ .

Finally, we estimate  $\bar{Q}_{W}^{a,1} = E[\bar{Q}_{L'}^{a,1}]$  as the empirical mean of the TMLE from the previous step:  $\bar{Q}_{W,n}^{a,1,*} = \frac{1}{n} \sum_{i=1}^{n} \bar{Q}_{L',n}^{a,1,*}(W_i)$ . This same estimate also gives the TMLE of  $\psi$ , since  $\psi(\bar{Q}^{a,1}) = \bar{Q}_{W}^{a,1}$ . Hence, the TMLE of  $\psi$  is  $\psi^* = \frac{1}{n} \sum_{i=1}^{n} \bar{Q}_{L',n}^{a,1,*}(W_i)$ .

In Appendix D we provide a concrete description of how to implement the IC-TMLE algorithm in practice.

### **5** Simulation Studies

In this section, we present simulations comparing our IC-TMLE procedure to several alternative methods: a TMLE ignoring interval censoring by using forward imputation (F-TMLE), a TMLE ignoring interval censoring by using only complete case data (CC-TMLE), a mean outcome within treatment groups using forward imputation (F-Mean), and a mean outcome within treatment groups using only complete case data (CC-Mean).

In each of our simulated datasets,  $A \sim Bern(0.5)$ , and hence, mean outcomes within treatment groups using only complete case data would be unbiased *if* censoring was uninformative. Also, note that both alternative TMLE procedures estimate well-defined effect measures *for the data structure they analyze* (forward imputed data, or complete case data), but nonetheless fail to take interval-censoring into account.

#### 5.1 Simulated Data Structure

Our simulated data structure is as follows. Two covariates  $(L_{t,1}, L_{t,2})$  collected over time, a binary treatment A assigned at baseline, and a binary outcome  $Y_t$  collected over time. The outcome at baseline is zero for all observations:  $Y_0 = 0$ . The covariates and outcome are collected at baseline t = 0, and at each of two subsequent follow-up times t = 1, 2. There is no censoring at baseline, so  $\Delta_0 = 1$ , but each subsequent follow-up time is subject to censoring. The outcome of interest is the outcome value at the final follow-up time  $\tau = 2$ .

Collection of Biostatistics Research Archive

#### 5.2 Motivating Example: Inadequacy of Parametric Models

To motivate our IC-TMLE approach, we begin by presenting a simulation demonstrating the failure of common logistic modeling approaches in the presence of interval censored data. Logistic regression is an example of a parametric statistical model, and hence makes the assumption that the data generating probability distribution is known up to a finite number of parameters. However, the underlying data generating distribution is generally always unknown in any experimental or observational study. Additionally, estimated odds ratios obtained via logistic regression are conditional on the remaining covariates in the model being held fixed. As a result, unless the logistic regression model is forced to not include interactions (which is not justifiable), the resulting odds ratios are functions of these remaining covariates, and hence are not well-defined effect measures. Furthermore, logistic modeling approaches commonly used by practitioners often ignore the interval censored structure of the data. Instead, ad hoc strategies such as complete case analysis or forward imputation are typically employed in an attempt to mask the interval censoring.

Our simulated data is generated as follows:

In the simulated data structure (14), the  $Y_t$  process is a time-to-event outcome since it begins at zero and and only jumps (at most) once to one. In the case of  $Y_1$ , this can be seen by observing that  $Y_0 = 0$ , and the Bernoulli term is either 0 or 1. For  $Y_2$ , the Bernoulli term is again either 0 or 1, and by taking the maximum with  $Y_1$ , we ensure that if  $Y_1$  already jumped to one,  $Y_2$  equals one.

Observe that A only affects the monitoring variables  $\Delta_1$  and  $\Delta_2$ . As a result, in truth, A has no effect on the outcome  $Y_2$ , since  $Y_2$  is not a function of either  $\Delta_1$  or  $\Delta_2$ . Hence, a successful logistic regression would estimate the coefficient of A to be zero.

We generated a sample of size 1,000 from (14), and fitted two types of logistic regression models to estimate the effect of A on  $Y_2$ . In the first, we employ

forward imputation to fill in the value of  $Y_2$  if  $\Delta_2 = 0$ , and regress  $Y_2$  onto A,  $W_1$ ,  $W_2$ . In the second, we use complete case analysis, and regress  $Y_2$  onto A,  $W_1$ ,  $W_2$ , but only among the observations with  $\Delta_2 = 1$ .

In the forward imputation approach, we obtain a coefficient estimate for *A* of -0.18, with a p-value of < 0.001, and a 95% confidence interval of (-0.24, -0.12). In the complete case analysis approach, we obtain a coefficient estimate for *A* of -0.18, with a p-value of < 0.001, and a 95% confidence interval of (-0.26, -0.09). Hence, both logistic regression approaches claim that *A* has a highly significant effect on *Y*<sub>2</sub>, when in reality no such effect exists.

#### **5.3** Simulation 1: No Effect of *A* on *Y*

In this simulation, we generated data from (14), as in Section 5.2. As described in the previous section, variable *A* has no effect on *Y*. The true values of  $\psi_1$  and  $\psi_0$  are both 0.64, and the true risk difference is  $\psi = \psi_1 - \psi_0 = 0$ . We performed 1000 simulations on each of sample sizes n = 200, 500, 1000. Results are presented in Table 1.

The IC-TMLE method shows strong performance. It has the lowest bias and MSE for  $\psi_1$  and  $\psi_0$  across all sample sizes. As sample size increases, bias and MSE decrease for all parameters. Coverage rate is high across all sample sizes, and improves with sample size.

Each of the other methods exhibit undesirable behavior. Bias for all parameters tends to stay constant with increasing sample size, and coverage rates decrease as sample size increases. Since the true value of  $\psi$  is zero, the low coverage rates mean that the competing methods tend to claim a significant effect, when in fact no such effect exists. At sample size 1000, each competing method has coverage rate under 5%, meaning that each competing method claims a false significant effect over 95% of the time.

Although F-MEAN has low bias for  $\psi$ , this is only due to the lucky fact that the large biases in  $\psi_1$  and  $\psi_0$  cancel out in the risk difference. Alternative parameters, e.g., relative risk, would not have bias cancellation. Even though F-MEAN's bias for  $\psi$  is low, coverage for  $\psi$  is poor. At sample size 200, F-MEAN has a coverage rate of roughly 31%, and by sample size 1000, the coverage rate has dropped to 0%.

#### **5.4** Simulation 2: *A* Affects *Y*

In this simulation, we generated data according to the laws below. Here, the variable A has a positive effect on Y. The true value of  $\psi_1$  is 0.80, the true value of  $\psi_0$  is

		IC-TMLE	F-TMLE	CC-TMLE	F-MEAN	CC-Mean
n = 200						
	BIAS					
	Ψ	-0.0670	-0.1661	-0.1475	-0.0001	-0.2216
	$\psi_1$	-0.0402	-0.3337	-0.0705	-0.3338	-0.1090
	$\psi_0$	0.0267	-0.1676	0.0770	-0.3337	0.1127
	MSE					
	$\psi$	0.0160	0.0323	0.0321	0.0321	0.0588
	$\psi_1$	0.0070	0.1136	0.0105	0.1136	0.0176
	$\psi_0$	0.0062	0.0307	0.0109	0.0308	0.0164
	COVER					
	Ψ	0.856	0.305	0.647	0.309	0.364
n = 500						
	BIAS					
	Ψ	-0.0164	-0.1673	-0.1553	-0.0001	-0.2260
	$\psi_1$	-0.0114	-0.3344	-0.0729	-0.3345	-0.1106
	$\psi_0$	0.0051	-0.1671	0.0823	-0.3344	0.1153
	MSE					
	Ψ	0.0039	0.0300	0.0279	0.0299	0.0546
	$\psi_1$	0.0018	0.1127	0.0074	0.1128	0.0143
	$\psi_0$	0.0018	0.0289	0.0086	0.0290	0.0148
	COVER					
	Ψ	0.959	0.029	0.265	0.029	0.038
n = 1000						
	BIAS					
	Ψ	0.0055	-0.1688	-0.1549	-0.0001	-0.2272
	$\psi_1$	0.0001	-0.3354	-0.0727	-0.3354	-0.1117
	$\psi_0$	-0.0046	-0.1666	0.0822	-0.3353	0.1157
	MSE					
	Ψ	0.0018	0.0295	0.0258	0.0295	0.0533
	$\psi_1$	0.0008	0.1129	0.0063	0.1129	0.0134
	$\psi_0$	0.0008	0.0282	0.0076	0.0282	0.0140
	COVER					
	ψ	0.979	0.000	0.046	0.000	0.000

Table 1: Simulation 1 results. The best performing method in each row is in bold.

0.72, and the true risk difference is  $\psi = \psi_1 - \psi_0 = 0.08$ .

COBRA A BEPRESS REPOSITORY Collection of Biostatistics Research Archive As in the previous simulation, we performed 1000 simulations from (15) on each of sample sizes n = 200, 500, 1000. Results appear in Table 2.

IC-TMLE has the lowest bias and highest coverage across all sample sizes. Bias and MSE decrease as sample increases, coverage and correctly signed confidence interval rates increase with sample size, and incorrectly signed confidence interval rate decreases as sample size increases.

Other methods show relatively constant bias with increasing sample size, lower coverage rate and fewer correctly signed confidence intervals with increasing sample size, and more incorrectly signed confidence intervals as sample size increases. A bias comparison for  $\psi_1$  is particularly informative: across all sample sizes, each of the competing methods retains high bias, while IC-TMLE starts out with the lowest bias and also steadily reduces bias at each increase in sample size. The competing methods are also particularly poor in terms of coverage: coverage rates are low, incorrect significant effects are often claimed, and correct significant effects are rarely found.

## 6 Data Analysis

#### 6.1 InC3 Data

The "International Collaboration of Incident HIV and HCV in Injecting Cohorts" (InC3) is a merged international multi-cohort project of pooled observational longitudinal data, both biological and behavioral, from 9 prospective cohorts of injection drug users (IDU). Hepatitis C virus (HCV) is a particularly common infection among injection drug users, and spontaneous viral clearance of HCV is often observed. However, the determinants of spontaneous viral clearance of HCV infection among injection drug users have not been extensively studied. Understanding the

Table 2: Simulation 2 results. The rows  $\psi$ ,  $\emptyset$  and  $\psi$ ,  $\emptyset$  indicate the fraction of 95% confidence intervals for  $\psi$  claiming a significant result with the correct (positive) sign and incorrect (negative) sign, respectively. The best performing method in each row is in bold.

r <u>ow is in b</u>	old.					
		IC-TMLE	F-TMLE	CC-TMLE	F-MEAN	CC-Mean
n = 200						
	BIAS					
	$\psi$	-0.0309	-0.1561	-0.0883	-0.0795	-0.0836
	$\psi_1$	-0.0190	-0.3824	-0.0624	-0.3822	-0.0605
	$\psi_0$	0.0118	-0.2263	0.0259	-0.3028	0.0231
	MSE					
	Ψ	0.0105	0.0296	0.0174	0.0298	0.0164
	$\psi_1$	0.0039	0.1488	0.0082	0.1487	0.0079
	$\psi_0$	0.0057	0.0537	0.0056	0.0536	0.0054
	COVER					
	$\psi$	0.924	0.387	0.810	0.396	0.836
	ψ, Ø	0.095	0.001	0.021	0.002	0.023
	¥,Ø	0.012	0.229	0.043	0.217	0.031
i = 500	// //					
	BIAS					
	Ψ	-0.0176	-0.1582	-0.0914	-0.0795	-0.0879
	$\psi_1$	-0.0128	-0.3838	-0.0651	-0.3837	-0.0639
	$\psi_0$	0.0048	-0.2256	0.0263	-0.3042	0.0239
	MSE	010010	012200	0.0200	0.0012	0.0207
	Ψ	0.0039	0.0270	0.0119	0.0271	0.0113
	$\psi_1$	0.0014	0.1483	0.0059	0.1482	0.0057
	$\psi_0$	0.0021	0.0518	0.0027	0.0518	0.0025
	COVER	0.0021	0.0010	0.0027	0.0010	0.0020
	ψ	0.943	0.047	0.647	0.064	0.687
	ψ, Ø	0.155	0.000	0.017	0.000	0.007
	ψ, ø ψ, ø	0.002	0.439	0.046	0.430	0.017
i = 1000	φ, φ	0.002	0.437	0.040	0.450	0.044
<i>n</i> = 1000	BIAS					
	ψ	-0.0118	-0.1591	-0.0935	-0.0795	-0.0899
	$\psi_1$	-0.0082	-0.3841	-0.0933	-0.3840	-0.0636
		0.0036	-0.2249	0.0288	-0.3045	0.0263
	$\psi_0$ MSE	0.0030	-0.2249	0.0288	-0.3043	0.0203
		0.0017	0.0262	0.0105	0.0262	0.0098
	Ψ					
	$\psi_1$	0.0006	0.1480	0.0050	0.1479	0.0049
	$\psi_0$	0.0010	0.0511	0.0018	0.0511	0.0017
	COVER	0.0(1	0.000	0.000	0.000	0.421
	Ψ	0.961	0.000	0.396	0.000	0.431
	ψ, Ø	0.303	0.000	0.008	0.000	0.013
	¥,Ø	0.000	0.723	0.047	0.718	0.039

A BEPRESS REPOSITORY

Collection of Biostatistics Research Archive factors that play a role in driving HCV clearance is of significant interest, as doing so would aid in the identification of risk factors for chronic infection, as well as suggest possible directions for pharmaceutical development.

Merge 1 data from the InC3 project consists of baseline and longitudinal data collected on 522 HCV infected injection drug users across the 9 study cohorts. Data about IDU from different cohorts are similar in several ways. For example, each cohort aimed to schedule regularly spaced visits for follow-up (although a scheduled visit is not the same as an *actual* visit!), and collected similar behavioral and biological measurements for each IDU. However, data about IDU from different follow-up intervals, and may not have collected all desired behavioral or biological measurements. As a result, the data is interval censored and consists of missing observations. Some IDU also received drug therapy to treat their HCV infection, resulting in right-censoring of the spontaneous clearance outcome. We refer to Grebely et al. (2012b) and the InC3 website (2013) for additional details about the InC3 cohort.

#### 6.2 Previous Work

Grebely et al. (2012a) used logistic regression to model the binary outcome of HCV clearance within 2 years of estimated incident infection as a function of variables of interest to analyze factors associated with spontaneous clearance. As demonstrated in Section 5.2, this type of forward imputation logistic regression modeling does not account for interval censoring, and often results in incorrect estimates and inference.

#### 6.3 Analysis

We apply IC-TMLE to estimate variable importance measures for the effects of age, ethnicity, gender, infecting genotype, and IL28B gene on the interval-censored outcome of spontaneous HCV clearance among injection drug users in the InC3 data. Following Grebely et al. (2012a), we defined clearance as two consecutive HCV RNA negative tests, and analyzed clearance within 2 years of incident infection. If clearance was observed for an IDU, all subsequent clearance outcomes were also set to clearance being true.

Since the focus of this paper is the interval censored nature of the clearance outcome, we handled interval-censoring of the initial infection date and rightcensoring of the outcome as follows. The first time infection was observed was used as the incident infection time t = 0. We used Inverse Probability of Censoring Weighting (IPCW) prior to applying the IC-TMLE procedure to account for

the right-censoring of spontaneous clearance for IDU who received drug therapy to treat their HCV infection. Using IPCW to weight the original observed data structure before applying a TMLE is sub-optimal, but still retains many desirable efficiency and robustness properties. For additional details, we refer to van der Laan and Rose (2011). The number of IDU not receiving HCV drug therapy is  $n_1 + n_0 = 429$ .

Given our assumed Structural Causal Model, variables included in *W* are different depending for each variable *A* we analyze. In particular, variables included in *W* cannot be affected by *A*. To account for this, we grouped available baseline variables into several categories (personal, date, location, gene, base-behavior, and age) describing their general type. Personal baseline variables included unchanging characteristics of study participants, such as gender, origin, and ethnicity. Date baseline variables included all year or date variables, such as birth date and cohort entry date. Location baseline variables included location-specific information, such as site and center. Gene baseline variables included values of all measured genes. Base-behavior variables included baseline information about injection and prison prior to HCV infection. Age baseline variables included the ages of the IDU at various life events, such as age at cohort entrance. Note that all of these variables are required to have occurred prior to HCV infection. If such information was not available (e.g., the participant was already infected with HCV upon entrance to a cohort), the variables were treated as missing.

When A represented IL28B or age, W included personal, date, location, gene, and age baseline variables. When A represented ethnicity or gender, W included personal, date, location, and gene baseline variables. When A represented infecting genotype, W included personal, date, location, gene, age, and base-behavior variables.

We analyzed factors A which had at least 15 IDU with A = 1. We did not analyze, for example, Asian ethnicity, since the number of Asian IDU was below 15. For this reason, the numbers within each variable analyzed do not necessarily sum to the total number of IDU within the dataset.

L' consisted of all baseline variables not included in W (and therefore is also different depending on A), as well as the time-dependent variables collected at the last monitoring time prior to 1 year after incident infection date.  $\Delta$  was an indicator of being monitored between 1 year and 2 years after incident infection date. Y was an indicator of whether clearance was observed between 1 year and 2 years after incident infection date. Note that, due to our definition of clearance, if clearance was observed prior to 1 year, and  $\Delta = 1$ , then Y = 1, as well. On the other hand, if clearance was observed prior to 1 year, but  $\Delta = 0$ , recall from Section 3.1.3 that we still effectively know that clearance has occurred, and our estimates will not be changed.

We selected the monitoring interval of between 1 and 2 years from incident infection date for several reasons. First, we are able to analyze all clearance prior to 2 years, as in Grebely et al. (2012a). Second, clearance of acute HCV infection typically occurs within 1 year of infection, as discussed in Page et al. (2009) and Grebely et al. (2012c). Third, using smaller intervals resulted in many fewer IDU being observed within the interval, resulting in poorer estimates. Together, this rationale was an attempt to balance the trade-off between, on the one hand, obtaining precise estimates through having a large enough number of IDU with  $\Delta = 1$ , and, on the other hand, obtaining results with strong interpretation by using a small window to examine the time-to-event outcome of clearance *at* a specific time.

#### 6.4 Results

The results of our analysis are presented in Table 3. Female gender, IL28B CC, and several middle age ranges showed a significantly positive effect on HCV clearance. Unknown gender, all other IL28B analyzed, unknown and indigenous ethnicity, infecting genotype 2 and 3, and several younger and older age ranges showed a significantly negative effect on HCV clearance.

It is important to note that estimates may be poor and confidence intervals may be overly optimistic (i.e., too small) when  $\min(n_0, n_1)$  is small, where  $n_1$  and  $n_0$  are the number of IDU with A = 1 and A = 0, respectively. For example, when  $\min(n_0, n_1)$  is small, our estimate of variance may not be able to detect whether the *true* variance of  $\psi$  is large. This is due to the fact that, in our case, the term  $g_A$  in the denominator of two of the influence curve components in (13) is the conditional probability that A = a given covariates W. We might expect  $g_A$  to be small, and hence, the variance to be large. However, for factors with small  $\min(n_0, n_1)$ , we may not observe participants where  $g_A$  is small, resulting in variance estimates and confidence intervals that are artificially small.

#### 6.5 Considerations for Future Analyses

While this paper's focus was on the interval censored nature of the HCV clearance outcome in the InC3 data, several other considerations would be fruitful for further analysis.

Future analysis should note that if the factor of interest A has a very small number of people (e.g., 21 participants with infecting genotype 2 in the Merge 1 InC3 dataset), the VIM of A may be excessively determined by the specific individuals within that small group. As a result, factors where  $\min(n_0, n_1)$  was very

Collection of Biostatistics Research Archive

	95% Sig	$\hat{m{\psi}}$	95% CI	$\min(n_0, n_1)$
Age				
Age < 20	$\checkmark$	-0.235	(-0.291, -0.178)	25
Age < 25	$\checkmark$	-0.154	(-0.232, -0.075)	179
Age < 30		0.011	(-0.071, 0.094)	120
Age < 35	$\checkmark$	0.147	(0.082, 0.213)	63
Age < 40	$\checkmark$	0.218	(0.160, 0.277)	34
Age 20-40	$\checkmark$	0.184	(0.129, 0.239)	69
Age 20-35	$\checkmark$	0.088	(0.024, 0.152)	98
Age 25-35		-0.040	(-0.152, 0.072)	187
Age 25-40	$\checkmark$	0.093	(0.012, 0.174)	213
Gender				
Male		-0.081	(-0.196, 0.035)	260
Female	$\checkmark$	0.125	(0.016, 0.233)	154
Unknown	$\checkmark$	-0.262	(-0.316, -0.208)	15
Genotype				
1		-0.029	(-0.136, 0.077)	157
2	$\checkmark$	-0.275	(-0.360, -0.190)	21
3	$\checkmark$	-0.125	(-0.214, -0.035)	97
Not Done		0.036	(-0.072, 0.145)	127
IL28B				
CC	$\checkmark$	0.194	(0.098, 0.291)	190
СТ	$\checkmark$	-0.165	(-0.260, -0.070)	146
TT	$\checkmark$	-0.181	(-0.288, -0.075)	46
Missing	$\checkmark$	-0.183	(-0.270, -0.097)	38
Ethnicity				
White		0.037	(-0.062, 0.135)	104
Indigenous	$\checkmark$	-0.251	(-0.340, -0.163)	31
Other		0.168	(-0.159, 0.495)	16
Unknown		-0.254	(-0.306, -0.202)	29

Table 3: InC3 analysis results. Check marks in the "95% Sig" column indicate that the analyzed variable had a significant effect on clearance, at the 95% level, and  $n_1$  and  $n_0$  are the number of IDU with A = 1 and A = 0, respectively.

small should be investigated further for a dataset with larger  $\min(n_0, n_1)$  to establish whether or not the effect remains. Furthermore, improved variance estimation methods for sparse data of this nature are needed.

Additional choices of the  $\Delta$  monitoring interval should also be studied. We attempted to balance the trade-off between precise and interpretable estimates, but additional analysis should be done to analyze the sensitivity of conclusions presented here to alternative choices of  $\Delta$ .

A BEPRESS REPOSITORY Collection of Biostatistics Research Archive

## 7 Discussion

While most experimental and observational data, particularly in genetics and epidemiology, is interval-censored, practitioners consistently fail to account for intervalcensored outcomes in their analyses of variable importance measures. In this paper, we demonstrated that ignoring interval-censored outcomes leads to biased estimates and incorrect inference. We presented a TMLE algorithm tailored for estimating VIM in the presence of interval-censored outcomes, IC-TMLE. We discussed the desirable statistical properties of IC-TMLE, showed its superior performance compared to other methods through a series of simulation studies, and used it to estimate VIM of spontaneous HCV clearance using the InC3 data.

The IC-TMLE procedure provides VIM estimates that can be used to determine the effects of a large collection of variables on an outcome subject to intervalcensoring. The ubiquity of interval-censored outcomes and the importance of obtaining valid variable importance measures indicate the wide-ranging applicability of our novel IC-TMLE approach to estimating VIM in the presence of intervalcensored outcomes.

## Funding

This work was supported by the National Science Foundation (Graduate Research Fellowship to Stephanie Sapp), the National Institutes of Health (5R01AI74345-4 to Mark J. van der Laan), and the National Institutes of Health National Institute on Drug Abuse (R01DA031056 to Kimberly Page).

## Acknowledgements

The authors thank the following investigators who contributed to InC3 data used in this paper: Julie Bruneau, Andrea Cox, Gregory Dore, Jason Grebely, Judith Hahn, Margaret Hellard, Georg Lauer, Andrew Lloyd, Arthur Kim, Lisa Maher, Barbara McGovern, Meghan Morris, Kimberly Page, Maria Prins, Thomas Rice, and Naglaa Shoukry.

COBRA A BEPRESS REPOSITORY Collection of Biostatistics Research Archive

# Appendices

## A Identifiability of Static Intervention Parameter

In an ideal (impossible) experiment, we would observe the static intervention (3) on all participants for both *a* values, and the causal effect of *A* on *Y* could be estimated by using the counterfactual outcomes to directly compute the empirical average  $\hat{\psi}_{static}^F = \frac{1}{n} \sum_{i=1}^{n} (Y_i^{1,1} - Y_i^{0,1})$ . Of course, in reality, we can never conduct the ideal experiment described by (3) (which explains why the data is called *counterfactual*). Instead, for (2) to be identifiable from the observed data, we need the following causal assumptions:

(C1)  $Y^{a,1} = Y^{A,1} | A = a$ 

Consistency 1: Intervening on the NPSCM to set treatment to A = a yields the observed data if the actual observed treatment is A = a.

(C2) 
$$Y^{A,1} = Y^{A,\Delta} | \Delta = 1$$

Consistency 2: Intervening on the NPSCM to set monitoring to  $\Delta = 1$  yields the observed data if the actual observed monitoring is  $\Delta = 1$ .

- (*R1*)  $Y^{a,1} \perp A \mid W$ Randomization 1: No unmeasured confounders associated with both treatment *A* and counterfactual outcome  $Y^{a,1}$ .
- (*R2*)  $Y^{a,1} \perp \Delta \mid W, A = a, L'$ Randomization 2: No unmeasured confounders associated with both monitoring  $\Delta$  and counterfactual outcome  $Y^{a,1}$ .
- (P1) P(A = a|W) > 0Positivity 1: Conditional probability of treatment, for both a = 1 and a = 0, is positive for all covariate possibilities *W*.
- (P2)  $P(\Delta = 1 | W, A = a, L') > 0$ Positivity 2: Conditional probability of monitoring at time  $\tau$  is positive for all covariate possibilities W, A, L'.

Under the above assumptions, we may express the components of  $\Psi_{static}^F$  as follows. Note that we use the shorthand notation  $E_{L'}$  to indicate the expectation with respect to the conditional distribution of  $L' \mid W, A = a$ . The abbreviation TR stands for the

COBRA A BEPRESS REPOSITORY Collection of Biostatistics Research Archive Tower Rule.

$$E[Y^{a,1}] \stackrel{(\mathrm{TR})}{=} E_{W}\left[E\left[Y^{a,1}|W\right]\right]$$

$$\stackrel{(\mathrm{R1}),(\mathrm{P1})}{=} E_{W}\left[E\left[Y^{a,1}|W,A=a\right]\right]$$

$$\stackrel{(\mathrm{C1})}{=} E_{W}\left[E\left[Y^{A,1}|W,A=a\right]\right]$$

$$\stackrel{(\mathrm{TR})}{=} E_{W}\left[E_{L'}\left[E\left[Y^{A,1}|W,A=a,L'\right]\right]\right]$$

$$\stackrel{(\mathrm{R2}),(\mathrm{P2})}{=} E_{W}\left[E_{L'}\left[E\left[Y^{A,1}|W,A=a,L',\Delta=1\right]\right]\right]$$

$$\stackrel{(\mathrm{C2})}{=} E_{W}\left[E_{L'}\left[E\left[Y^{A,\Delta}|W,A=a,L',\Delta=1\right]\right]\right]$$
(16)

Equation (16) is a function of the distribution of the observed data, allowing us to identify (2) from the observed data.

# **B** Identifiability of Stochastic Intervention Parameter

Ideally, we would observe the stochastic intervention (7) on all participants for both *a* values, and the causal effect of *A* on *Y* could be estimated by using the counterfactual outcomes to directly compute the empirical average  $\hat{\psi}_{stochastic}^F = \frac{1}{n} \sum_{i=1}^{n} (Y_i^{\#,1,\delta} - Y_i^{\#,0,\delta})$ . Since the ideal experiment described by (7) is not possible, for (6) to be identifiable from the observed data, we need the following causal assumptions:

(C1)  $Y^{\#,a,\delta} = Y^{\#,A,\delta} | A = a$ (C2)  $Y^{\#,A,\delta} = Y^{\#,A,\Delta^{\#}} | \Delta^{\#} = \delta$ (R1)  $Y^{\#,a,\delta} \perp \perp A | W$ (R2)  $Y^{\#,a,\delta} \perp \perp \Delta^{\#} | W, A = a, L'^{\#}$ (P1) P(A = a | W) > 0(P2)  $P(\Delta^{\#} = \delta | W, A = a, L'^{\#}) > 0$  Under the above assumptions, we may express the components of  $\psi^F_{stochastic}$  as follows:

$$E[Y^{\#,a,\delta}] \stackrel{(\mathrm{TR})}{=} E_{W}\left[E\left[Y^{\#,a,\delta}|W\right]\right]$$

$$\stackrel{(\mathrm{R1}),(\mathrm{P1})}{=} E_{W}\left[E\left[Y^{\#,a,\delta}|W,A=a\right]\right]$$

$$\stackrel{(\mathrm{C1})}{=} E_{W}\left[E\left[Y^{\#,\delta}|W,A=a\right]\right]$$

$$\stackrel{(\mathrm{TR})}{=} E_{W}\left[E_{L'^{\#}}\left[E\left[Y^{\#,\delta}|W,A=a,L'^{\#}\right]\right]\right]$$

$$\stackrel{(\mathrm{R2}),(\mathrm{P2})}{=} E_{W}\left[E_{L'^{\#}}\left[E\left[Y^{\#,\delta}|W,A=a,L'^{\#},\Delta^{\#}=\delta\right]\right]\right]$$

$$\stackrel{(\mathrm{C2})}{=} E_{W}\left[E_{L'^{\#}}\left[E\left[Y^{\#}|W,A=a,L'^{\#},\Delta^{\#}=\delta\right]\right]\right] (17)$$

As before, the last equation above is a function of the distribution of the observed data, allowing us to identify (6) from the observed data.

## **C Proof of Equivalence of Intervention Formulations**

Under the stochastic intervention, from equation (17), we have that

$$E[Y^{\#,a,\delta}] = E_W \left[ E_{L'^{\#}} \left[ E \left[ Y^{\#} \middle| W, A = a, L'^{\#}, \Delta^{\#} = \delta \right] \right] \right]$$
  
=  $E_W \left[ E_{L'^{\#}} \left[ E \left[ Y^{\#}(\tau - 1) + (1 - Y^{\#}(\tau - 1)) Y^{*}(\tau) \middle| W, A = a, L'^{\#}, \Delta^{\#} = \delta \right] \right] \right]$   
=  $E_W \left[ E_{L'^{\#}} \left[ Y^{\#}(\tau - 1) + (1 - Y^{\#}(\tau - 1)) E \left[ Y^{*}(\tau) \middle| W, A = a, L'^{\#}, \Delta^{\#} = \delta \right] \right] \right]$ (18)

Now, since  $Y^{\#}(\tau - 1) \in L'^{\#}$  and  $Y^{\#}(\tau - 1)$  is binary, we can simplify  $E\left[ \left[ Y^{*}(\tau) \right]_{W} \right]_{W} = \left[ \left[ Y^{*}(\tau) \right]_{W} \right]_{W} = \left[ \left[ Y^{*}(\tau) \right]_{W} \right]_{W}$ 

$$E\left[Y^{*}(\tau)\middle|W, A = a, L^{'\#}, \Delta^{\#} = \delta\right]$$
(19)

by considering the value of  $Y^{\#}(\tau - 1)$  and the definition of  $\delta$ :

A BEPRESS REPOSITORY Collection of Biostatistics Research Archive

$$(19) = E\left[Y^{*}(\tau)\middle|W, A = a, L'^{\#}, \Delta^{\#} = (1 - Y^{\#}(\tau - 1)) + Y^{\#}(\tau - 1)\Delta^{\#}(\tau - 1)\right]$$
  
$$= E\left[Y^{*}(\tau)\middle|W, A = a, L'^{\#}, \Delta^{\#} = 1\right]Y^{\#}(\tau - 1) + E\left[Y^{*}(\tau)\middle|W, A = a, L'^{\#}, \Delta^{\#} = 1\right](1 - Y^{\#}(\tau - 1))$$
  
$$= E\left[Y^{*}(\tau)\middle|W, A = a, L'^{\#}, \Delta^{\#} = 1\right]$$
(20)

The above calculations hold because, no matter the value of  $Y^{\#}(\tau - 1)$ , the stochastic intervention results in  $\Delta^{\#} = 1$ . This can be seen by noting that if  $Y^{\#}(\tau - 1) = 1$ , then  $\Delta^{\#}(\tau - 1) = 1$ , resulting in  $\Delta^{\#}(\tau) = 1$ . On the other hand, if  $Y^{\#}(\tau - 1) = 0$ , the stochastic intervention also tells us to set  $\Delta^{\#}(\tau) = 1$ . Now, using the equality of (19) and (20), we can simplify equation (18) as:

(18) = 
$$E_W \left[ E_{L'^{\#}} \left[ Y^{\#}(\tau - 1) + (1 - Y^{\#}(\tau - 1)) E \left[ Y^{*}(\tau) \middle| W, A = a, L'^{\#}, \Delta^{\#} = 1 \right] \right] \right]$$
(21)

Under the static intervention, from equation (16), we have:

$$E[Y^{a,1}] = E_W \left[ E_{L'} \left[ E \left[ Y^*(\tau) | W, A = a, L', \Delta = 1 \right] \right] \right]$$
  
=  $E_W \left[ E_{L'} \left[ E \left[ Y^*(\tau) | W, A = a, L', \Delta = 1, Y^{\#}(\tau - 1) = 1 \right] Y^{\#}(\tau - 1) + E \left[ Y^*(\tau) | W, A = a, L', \Delta = 1, Y^{\#}(\tau - 1) = 0 \right] (1 - Y^{\#}(\tau - 1)) \right] \right]$   
=  $E_W \left[ E_{L'} \left[ Y^{\#}(\tau - 1) + (1 - Y^{\#}(\tau - 1)) E \left[ Y^*(\tau) | W, A = a, L', \Delta = 1 \right] \right] \right] (22)$ 

To see the equivalence of (21) and (22), observe that the only difference lies in the use of L' versus  $L'^{\#}$ . However, L' and  $L'^{\#}$  contain equivalent information:  $L'^{\#}$  was constructed from L', which shows that any information contained in  $L'^{\#}$ is also contained in L', and on the other hand, the data redefinition equations can easily be used to derive L' from  $L'^{\#}$ . Finally, since both versions of the data contain identical information, the causal assumptions needed for identifiability are also interchangeable.

## **D** Practical IC-TMLE Algorithm Implementation

To clarify the description of IC-TMLE provided in the main article, we provide here a more concrete and detailed description of the practical steps needed to implement

```
the algorithm.
```

#### **IC-TMLE** algorithm

- 0. Obtain initial estimators  $g_{A,n}(a|w)$  of  $g_A(a|w)$  and  $g_{\Delta,n}(1|w,a,l')$  of  $g_{\Delta}(1|w,a,l')$  using Super Learning.
- 1. Obtain initial estimator  $\bar{Q}_{Y,n}^{a,1}$  of  $\bar{Q}_Y^{a,1}$  by using Super Learning to perform logistic regression of *Y* onto *W* and *L'* among the observations with A = a and  $\Delta = 1$ .
- 2. Fit a parametric logistic regression, among observations with A = a and  $\Delta = 1$ , of *Y* onto clever covariate  $\frac{I(A = a)I(\Delta = 1)}{g_{A,n}(a)g_{\Delta,n}(1)}$ , offset by the fitted values from  $\bar{Q}_{Y,n}^{a,1}$  (making sure to set these fitted values equal to 1 for any observations with  $Y_t = 1$  for some  $Y_t \in L'$ ). Obtain  $\bar{Q}_{Y,n}^{a,1,*}$ .
- 3. Obtain initial estimator  $\bar{Q}_{L',n}^{a,1}$  of  $\bar{Q}_{L'}^{a,1}$  by using Super Learning to perform logistic regression of  $\bar{Q}_{Y,n}^{a,1,*}$  onto W, among the observations with A = a. Note that we calculate the clever covariate of  $\bar{Q}_{Y,n}^{a,1,*}$  as  $\frac{I(A = a) [I(\Delta = 1) = 1]}{g_{A,n}(a)g_{\Delta,n}(1)}$ , i.e., we calculate the clever covariate setting A = a and  $\Delta = 1$  for all observations with A = a. Similarly, we calculate the offset of  $\bar{Q}_{Y,n}^{a,1,*}$  using predictions from  $\bar{Q}_{Y,n}^{a,1}$  for all observations with A = a. Furthermore, if a built-in method to obtain predictions from a glm object with offset is not available (e.g., R),  $\bar{Q}_{Y,n}^{a,1,*}$  must be calculated manually.
- 4. Fit a parametric logistic regression, among observations with A = a, of Q
  <sup>a,1,\*</sup>
  (calculated as described in the previous step) onto clever covariate 
  <sup>I(A = a)</sup>/<sub>g<sub>A,n</sub>(a)</sub>,
  offset by the fitted values from Q
  <sup>a,1</sup>/<sub>L',n</sub> (note that we do not need to set any of
  these fitted values equal to 1, since Y<sub>0</sub> = 0 for all observations). Obtain Q
  <sup>a,1,\*</sup>/<sub>L',n</sub>
  5. Estimate Q
  <sup>a,1</sup>/<sub>W</sub> with the empirical mean Q
  <sup>a,1</sup>/<sub>W,n</sub> = <sup>1</sup>/<sub>n</sub> ∑
  <sup>n</sup>/<sub>L',n</sub> (W<sub>i</sub>). This is also
  the TMLE Q
  <sup>a,1,\*</sup>/<sub>W,n</sub>, as well as the TMLE of ψ(Q
  <sup>a,1,\*</sup>), since Q
  <sup>a,1,\*</sup>/<sub>W,n</sub> = ψ(Q
  <sup>a,1,\*</sup>).
  Note that we calculate Q
  <sup>a,1,\*</sup>/<sub>L',n</sub> among all observations, and the procedure is

analogous to the procedure for calculating  $\bar{Q}_{Y,n}^{a,1,*}$  described above. To be explicit, we obtain the offset using the predictions from  $\bar{Q}_{L',n}^{a,1}$  for all observations, set the clever covariate to the case that A = a for all observations, and calculate the predictions from a glm object with offset (manually, if needed).

Collection of Biostatistics Research Archive

## References

- Bembom, O., M. Petersen, S.-Y. Rhee, W. Fessel, S. Sinisi, R. Shafer, and M. van der Laan (2009): "Biomarker discovery using targeted maximumlikelihood estimation: Application to the treatment of antiretroviral-resistant HIV infection," *Statistics in Medicine*, 28, 152–172.
- Cai, T. and R. Betensky (2003): "Hazard regression for interval-censored data with penalized spline," *Biometrics*, 59, 570–579.
- Carone, M., M. Petersen, and M. van der Laan (2012): "Targeted minimum lossbased estimation of a causal effect using interval-censored time-to-event data," in *Interval-Censored Time-to-Event Data: Methods and Applications*, Chapman and Hall/CRC.
- Finkelstein, D. (1986): "A proportional hazards model for interval-censored failure time data," *Biometrics*, 42, 845–854.
- Geskus, R. and P. Groeneboom (1999): "Asymptotically optimal estimation of smooth functionals for interval censoring, case 2," *The Annals of Statistics*, 27, 627–674.
- Grebely, J., G. Dore, M. S. van der Loeff, and T. Rice and A.L. Cox and J. Bruneau and A.Y. Kim and J. George and L. Maher and A.R. Lloyd and M. Hellard and K. Page and M. Prins and on behalf of the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) (2012a): "Female sex and variations in IL28B are independently associated with spontaneous clearance of acute HCV infection," 8th Australasian Viral Hepatitis Conference, Auckland, New Zealand.
- Grebely, J., M. Morris, T. Rice, and J. Bruneau and A.L. Cox and A. Kim and B. McGovern and N. Shoukry and G. Lauer and L. Maher and A.R. Lloyd and M. Hellard and M. Prins and G.J. Dore and K. Page (2012b): "Cohort profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) study," *International Journal of Epidemiology*, in press.
- Grebely, J., M. Prins, M. Hellard, and A.L. Cox and W.O. Osburn and G. Lauer and K. Page and A.R. Lloyd and G.J. Dore (2012c): "Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine," *The Lancet Infectious Diseases*, 12, 408–414.
- Groeneboom, P. and J. Wellner (1992): Information Bounds and Nonparametric Maximum Likelihood Estimation, Boston: Birkhauser.
- Gruber, S. and M. van der Laan (2010): "A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome," *The International Journal of Biostatistics*, 6.
- Huang, J. and J. Wellner (1997): "Interval censored survival data: A review of recent progress," in D. Lin and T. Fleming, eds., *Proceedings of the First Seattle*

Posograh Arabiya

*Symposium in Biostatistics: Survival Analysis*, New York: Springer-Verlag, 123–169.

InC3 website (2013): URL https://inc3.epi-ucsf.org.

- Page, K., J. Hahn, J. Evans, and S. Shiboski and P. Lum and E. Delwart and L. Tobler and W. Andrews and L. Avanesyan and S. Cooper and M.P. Busch (2009):
  "Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection," *Journal of Infectious Diseases*, 200, 1216–1226.
- Pearl, J. (2000): *Causality: Models, Reasoning and Inference*, Cambridge University Press.
- Rabinowitz, D., R. Betensky, and A. Tsiatis (2000): "Using conditional logistic regression to fit proportional odds models to interval censored data," *Biometrics*, 56, 511–518.
- Rabinowitz, D., A. Tsiatis, and J. Aragon (1995): "Regression with intervalcensored data," *Biometrika*, 82, 501–513.
- Rossini, A. and A. Tsiatis (1996): "A semiparametric proportional odds regression model for the analysis of current status data," *Journal of the American Statistical Association*, 91, 713–721.
- Tian, L. and T. Cai (2006): "On the accelerated failure time model for current status and interval censored data," *Biometrika*, 93, 329–342.
- van der Laan, M. and S. Gruber (2011): "Targeted minimum loss based estimation of an intervention specific mean outcome," Technical report, U.C. Berkeley Division of Biostatistics Working Paper Series.
- van der Laan, M., E. Polley, and A. Hubbard (2007): "Super learner," *Statistical Applications in Genetics and Molecular Biology*, 6.
- van der Laan, M. and S. Rose (2011): *Targeted Learning: Causal Inference for Observational and Experimental Data*, Berlin/Heidelberg/New York: Springer.
- van der Laan, M. and D. Rubin (2006): "Targeted maximum likelihood learning," *The International Journal of Biostatistics*, 2.

COBRA A BEPRESS REPOSITORY Collection of Biostatistics Research Archive